Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study

Podobné jednotky

• The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
  Autor: Jung, Hyun Ae, a další
  Vydáno: (2020)
• First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting
  Autor: Park, Keunchil, a další
  Vydáno: (2019)
• Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
  Autor: Paz-Ares, L., a další
  Vydáno: (2017)
• Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
  Autor: E-E Ke, a další
  Vydáno: (2016-06-01)
• Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
  Autor: Ke, E-E, a další
  Vydáno: (2016)